The University of North Carolina at Chapel Hill is a public research university in Chapel Hill, North Carolina. The flagship of the University of North Carolina system, it is considered a Public Ivy, or a public institution which offers an academic experience similar to that of an Ivy League university.

During the past decade, Unc Aids Crs conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 18 clinical trials were completed, i.e. on average, 85.7% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 7 clinical trials were completed. i.e. 70% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Unc Aids Crs" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 97 trials, followed by "AIDS Clinical Trials Group" with 4 trials sponsored, "COVID-19 Prevention Network" with 1 trials sponsored, "HIV Prevention Trials Network" with 1 trials sponsored and "HIV Vaccine Trials Network" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Unc Aids Crs" #1 collaborator was "Glaxo Wellcome" with 10 trials as a collaborator, "AIDS Clinical Trials Group" with 8 trials as a collaborator, "National Institute of Allergy and Infectious Diseases (NIAID)" with 7 trials as a collaborator, "Bristol-Myers Squibb" with 5 trials as a collaborator and "Hoffmann-La Roche" with 4 trials as a collaborator. Other collaborators include 32 different institutions and companies that were collaborators in the rest 33 trials.

According to Clinical.Site data, the most researched conditions in "Unc Aids Crs" are "HIV Infections" (93 trials), "HIV Infection" (5 trials), "Pneumonia, Pneumocystis Carinii" (4 trials), "Cytomegalovirus Retinitis" (3 trials) and "Mycobacterium Avium-intracellulare Infection" (3 trials). Many other conditions were trialed in "Unc Aids Crs" in a lesser frequency.

Most popular intervention types in "Unc Aids Crs" are "Drug" (84 trials), "Biological" (19 trials), "Other" (4 trials), "Dietary Supplement" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Zidovudine" (21 trials), "Placebo" (12 trials), "Didanosine" (10 trials), "Lamivudine" (10 trials) and "Stavudine" (9 trials). Other intervention names were less common.

The vast majority of trials in "Unc Aids Crs" are 98 trials for "All" genders, 5 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Unc Aids Crs". undefined are not yet recruiting, 4 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 93 completed trials in Unc Aids Crs, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Unc Aids Crs, 23 "Phase 1" clinical trials were conducted, 50 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 7 trials that are defined as “Not Applicable".